PEOPLE - Changes at Interleukin Genetics:
This article was originally published in Clinica
Executive Summary
Interleukin Genetics, a Waltham, Massachusetts-based developer of gene-based inflammatory response risk-assessment and pharmacogenetic tests, has announced changes to its executive management team. Kenneth Kornman, founder, president and chief scientific officer, will also assume the role of CEO, replacing Philip Reilly, who continues as chairman of the board of directors; and Gregg Mayer, most recently the vice-president of strategic marketing and communications at EPIC Pharmaceuticals, has been appointed as chief business officer.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.